Oral Biolife has appointed Thomas J. Corrigan, CPA, as Vice President of Finance to strengthen its financial strategy and support the biotechnology company’s next phase of growth.
Corrigan brings more than 25 years of experience in financial strategy, capital allocation, mergers and acquisitions, operational planning and business transformation across global healthcare and life sciences organizations.
In his new role, Corrigan will oversee Oral Biolife’s financial strategy, capital management, investor readiness, financial controls and operational planning.
He will also support future fundraising initiatives, commercialization planning and the development of the financial infrastructure needed to advance Oral Biolife’s regenerative medicine platform.
Corrigan joins Oral Biolife after spending 17 years in financial leadership roles at Novartis. He previously held finance positions at Johnson & Johnson and PwC.
Throughout his career, Corrigan has worked with executive leadership teams to assess investments, manage complex business portfolios and align financial decisions with long-term growth objectives.
His experience also includes supporting strategic transactions, allocating capital across healthcare businesses and helping organizations navigate periods of operational change.
Oral Biolife said the appointment comes as the company continues advancing its non-surgical, piezoelectric regenerative platform across dental and orthopedic applications.
The company’s technology is designed to convert naturally occurring mechanical forces within the body into localized bioelectric signals that stimulate physiological bone formation.
This approach is intended to provide a mechanical foundation for regenerative therapies that promote the body’s natural healing processes.
Oral Biolife’s lead human product candidate is Ambrilux Dental Gel, which is in clinical development for periodontal bone regeneration.
Periodontal disease can damage the bone and tissue supporting the teeth. Oral Biolife is developing Ambrilux as a non-surgical treatment intended to stimulate localized bone regeneration in affected areas.
The company is also developing applications for orthopedic indications, creating opportunities to use the same underlying regenerative platform across multiple areas of care.
Oral Biolife’s veterinary product, Restoris, was launched in 2025 through a partnership with Phibro Animal Health Corporation.
The commercialization of Restoris provides Oral Biolife with experience in bringing a product based on its platform to market while the company continues developing its human clinical programs.
As Vice President of Finance, Corrigan will help prepare the company for the financial and operational requirements associated with clinical development, regulatory progress and potential commercialization.
Biotechnology companies advancing clinical-stage products often require significant capital to support research, clinical trials, manufacturing, regulatory submissions and commercial preparations.
Corrigan’s responsibilities will include helping Oral Biolife evaluate capital requirements, establish financial controls and prepare for discussions with investors and strategic partners.
He will also work with the company’s leadership team to prioritize investments and allocate resources across product development, operations and growth initiatives.
Oral Biolife believes Corrigan’s experience within large healthcare organizations will help the company build systems capable of supporting its transition into a more mature biotechnology business.
In addition to his corporate leadership experience, Corrigan was a founding board member of Avery’s Hope, a nonprofit organization that assists families affected by rare diseases.
He is a Certified Public Accountant and brings a collaborative, data-driven approach to financial leadership and organizational development.
Oral Biolife is headquartered in Denver and is focused on developing regenerative medicine products that use bioelectric signaling to activate bone formation.
KEY QUOTES:
“Tom brings an exceptional combination of financial leadership, strategic planning, and healthcare industry experience. As we continue advancing our regenerative technology platform, his expertise will help strengthen our financial operations, support future fundraising efforts, and position the company for long-term growth.”
Dr. Stella Vnook, Founder and President of Oral Biolife
“I’m excited to join Oral Biolife at such a pivotal stage in the company’s growth. OBL has built a differentiated platform addressing large, underserved markets in dental and orthopedic care, and the momentum already underway made this an easy decision. I look forward to building the financial infrastructure to support commercialization, strategic growth, and long-term value creation.”
Thomas J. Corrigan, Vice President of Finance at Oral Biolife
